Jeffrey Black - Exagen Chief Officer

XGN Stock  USD 4.05  0.05  1.22%   

Executive

Jeffrey Black is Chief Officer of Exagen Inc
Age 55
Address 1261 Liberty Way, Vista, CA, United States, 92081
Phone760 560 1501
Webhttps://www.exagen.com

Jeffrey Black Latest Insider Activity

Tracking and analyzing the buying and selling activities of Jeffrey Black against Exagen stock is an integral part of due diligence when investing in Exagen. Jeffrey Black insider activity provides valuable insight into whether Exagen is net buyers or sellers over its current business cycle. Note, Exagen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Exagen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Exagen Management Efficiency

The company has Return on Asset of (0.1741) % which means that on every $100 spent on assets, it lost $0.1741. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6997) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Exagen's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Intangible Assets is likely to grow to about 6.6 M, while Total Assets are likely to drop about 54.2 M.
Exagen Inc has 23.72 M in debt with debt to equity (D/E) ratio of 0.55, which is OK given its current industry classification. Exagen Inc has a current ratio of 9.11, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Exagen to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Benjamin JDSera Prognostics
45
Jessica OlbrichtBiodesix
N/A
Kieran OKaneBiodesix
47
Dror BacherDarioHealth Corp
49
Josh FischerDarioHealth Corp
N/A
Kat ParrellaDarioHealth Corp
N/A
Mary MooneyDarioHealth Corp
N/A
Hao LiuBurning Rock Biotech
50
Tobin JuvenalCastle Biosciences
64
Kathleen HoffmanSotera Health Co
N/A
Daniella MehalikPsychemedics
34
Mona DeanDarioHealth Corp
N/A
Xiaozhi HuBurning Rock Biotech
N/A
Robbie LuntBiodesix
N/A
Danielle MentureSotera Health Co
N/A
Austin AertsSera Prognostics
37
Kristen RNCastle Biosciences
56
Patrick KinneyPsychemedics
N/A
Kevin DomanCastle Biosciences
N/A
Claudia LeviDarioHealth Corp
N/A
Omar MDDarioHealth Corp
N/A
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. Exagen Inc (XGN) is traded on NASDAQ Exchange in USA. It is located in 1261 Liberty Way, Vista, CA, United States, 92081 and employs 174 people. Exagen is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Exagen Inc Leadership Team

Elected by the shareholders, the Exagen's board of directors comprises two types of representatives: Exagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exagen. The board's role is to monitor Exagen's management team and ensure that shareholders' interests are well served. Exagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffrey Black, Chief Officer
Debra Zack, Chief Officer
John Wegener, Senior Marketing
Ryan Douglas, Investors Officer
Mark Hazeltine, Chief Officer
MingChou Lee, Chief Officer
John Aballi, President, CEO
Michael MD, Chief Officer
MD FACR, Chief Board
MBA MS, Corporate Secretary
Tina Nova, Executive Directors

Exagen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Moving against Exagen Stock

  0.46MLYS Mineralys Therapeutics,PairCorr
  0.44KA Kineta IncPairCorr
  0.42TCHH Trustcash HoldingsPairCorr
  0.41PFE Pfizer Inc Aggressive PushPairCorr
  0.32EQ EquilliumPairCorr
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.94)
Revenue Per Share
3.163
Quarterly Revenue Growth
0.066
Return On Assets
(0.17)
Return On Equity
(0.70)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.